Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times
| Authors | |
|---|---|
| Year of publication | 2020 |
| Type | Article in Periodical |
| Citation | |
| web | https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/dad2.12081 |
| Doi | http://dx.doi.org/10.1002/dad2.12081 |
| Keywords | Alzheimer's disease; blood-based biomarker; disease-modifying treatment; health system capacity; simulation |
| Description | IntroductionConcerns have been raised about the limited health system capacity for identification of patients who are eligible for a disease-modifying Alzheimer's treatment (DMT). Blood-based biomarker (BBBM) tests are a promising tool to improve triaging at the primary care level. We projected their impact on cost of and wait times during the diagnostic process. |